# Ipamorelin Research: Mechanism, Key Studies and the Evidence Map > Ipamorelin research, organized: the GHS-R1a mechanism, the human PK and failed Phase 2 data, the rodent bone and weight findings, and the class-level combination evidence. What was measured, in which species, at what dose — with ipamorelin's own data kept separate from the broader peptide-class evidence. ## Start here Ipamorelin research divides into two tiers, and keeping them apart is the whole point of an honest digest. The first tier is studies of ipamorelin itself: a founding pharmacology paper, a human pharmacokinetic study, one failed human trial, and a handful of rodent experiments on bone and weight. The second tier is class-level evidence — work done with ipamorelin's chemical relatives (GHRP-6, GHRP-2, hexarelin, CJC-1295) that explains how the family behaves but does not, on its own, prove anything about ipamorelin specifically. This page walks the mechanism first, in plain terms — how a five-amino-acid peptide flips a receptor switch to release growth hormone — then lays the studies out tier by tier. Where a claim leans on a relative rather than on ipamorelin, the text says so. Jargon is unpacked the first time it appears. ## What is ipamorelin peptide, structurally Ipamorelin peptide is a synthetic pentapeptide — five amino acids in a chain — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1]. Two of those building blocks are mirror-image (D-form) amino acids and one is a non-natural unit (Aib, alpha-aminoisobutyric acid) sitting at the front of the chain; together they make the molecule harder for the body's enzymes to chew up [1]. It was derived from an earlier peptide, GHRP-1, by removing a central two-amino-acid segment. Its molecular weight is about 712 daltons. Chemically, then, it is a deliberately engineered, protease-resistant ghrelin mimic — built to do one job, release growth hormone, with as little off-target noise as possible [1]. ## What does ipamorelin peptide do at the receptor What ipamorelin peptide does, in mechanism, is bind and activate the GHS-R1a — the growth-hormone secretagogue receptor type 1a, better known as the ghrelin receptor — on pituitary somatotrophs (the growth-hormone-making cells) [1]. Activation runs through a Gq/phospholipase-C cascade that raises intracellular calcium and triggers a discrete pulse of growth-hormone release [1]. The defining result from the 1998 characterization: potent growth-hormone release comparable to GHRP-6, but with no meaningful rise in ACTH or cortisol even more than two-hundred-fold above the growth-hormone ED50 — the selectivity that names the compound [1]. Downstream, growth hormone can raise hepatic IGF-1, but notably the short rat bone study saw skeletal growth without a measurable systemic IGF-1 change, hinting at a partly local, pulse-driven effect [4]. ## The human evidence: pharmacokinetics and one failed trial Two human datasets anchor everything. The first, a 1999 population pharmacokinetic-pharmacodynamic study in healthy men (n=8 per dose, five intravenous infusions from 4.21 to 140.45 nmol/kg), found dose-proportional kinetics, a terminal half-life of roughly two hours, clearance of 0.078 L/h/kg, and a single growth-hormone pulse peaking near forty minutes [2]. The second is the decisive one: a 2014 Phase 2 randomized controlled trial (NCT00672074) gave 114 bowel-resection patients 0.03 mg/kg intravenously twice daily for up to seven days to speed bowel recovery. It missed its primary endpoint — first tolerated meal at 25.3 hours versus 32.6 hours on placebo (p=0.15) — though it raised no ipamorelin-specific safety alarm in that short window (treatment-emergent adverse events 87.5 percent versus 94.8 percent on placebo) [3]. That is the entire controlled human efficacy record, and it is negative. ## Rodent and animal findings: bone and weight Animal work is where ipamorelin's positive signals live. In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90 and 450 micrograms per day (split three times daily for fifteen days) raised the long-bone growth rate from 42 to 44, 50 and 52 micrometres per day, dose-dependently, with no change in total IGF-1 or bone-turnover markers [4]. In the most recent published in-vivo study, a 2024 ferret cachexia model, intraperitoneal ipamorelin at 1 to 3 mg/kg cut cisplatin-driven weight loss by about 24 percent in the delayed phase, though it produced no anti-emetic effect [5]. Both are clean, cited animal findings. Neither has a human counterpart, and the leap from a ferret's body weight to a person's body composition is exactly the leap the marketing makes and the evidence does not. ## Class-level combination evidence: real, but not about ipamorelin alone The synergy that justifies stacking is demonstrated across the peptide family, not in ipamorelin head-to-head trials. In rats neutralized of their own growth-hormone-releasing hormone, exogenous GHRH plus a GHRP produced growth-hormone peaks greater than the sum of each alone [8], and blocking endogenous GHRH attenuated GHRP-6 activity — proving GHRH tone is required for a secretagogue to work fully [9]. In growth-hormone-releasing-hormone-knockout mice, a GHRH analog plus GHRP-2 produced more growth than the analog alone, while GHRP-2 by itself did nothing [10]. A human study with hexarelin showed a GHRP-plus-GHRH combination kept releasing growth hormone even under high somatostatin (the body's "stop" signal) that blunted GHRH alone [7]. A comprehensive review confirms this is a class-wide property of all GH secretagogues [12]. Every one of these uses a relative of ipamorelin — the principle is sound, the ipamorelin-specific combination trial does not exist. ## The somatostatin angle, which the combination exploits One mechanistic detail explains why the peptide class is so effective in combination, and it is worth stating plainly. The body restrains growth-hormone release with somatostatin, a "stop" signal. Growth-hormone-releasing hormone struggles against high somatostatin tone — but ghrelin and its synthetic mimics both directly stimulate the growth-hormone-making cells and indirectly damp the somatostatin brake, providing two-sided amplification when paired with a GHRH analog [14]. A human study with hexarelin made this concrete: a GHRP-plus-GHRH combination kept producing large growth-hormone responses even under high somatostatin infusion that largely flattened GHRH alone [7]. Comprehensive reviews place this somatostatin-resistance among the class-wide properties of all growth-hormone secretagogues, ipamorelin's structural family included [12]. This is the real pharmacological reason ipamorelin is studied beside a GHRH analog rather than alone — though, again, the demonstrations use relatives, not ipamorelin in a combination trial. ## Reading the evidence honestly Put together, the ipamorelin research tells a coherent and modest story. The mechanism is well characterized and genuinely distinctive — a clean, cortisol-sparing growth-hormone pulse [1]. The human pharmacokinetics are known [2]. The animal efficacy signals on bone [4] and weight preservation [5] are real but species-bound. And the one place the rubber met the road in humans, a controlled efficacy trial, it did not deliver [3]. The combination pharmacology is sound at the class level [9][10], but the specific ipamorelin-plus-GHRH-analog product has never been put to a trial. A reader is well served by holding two ideas at once: ipamorelin is a real, interesting, selective tool with a coherent mechanism, and its human benefit for the purposes it is marketed toward remains unproven. Both statements are true, and a vetted digest refuses to drop either one. ## Is ipamorelin FDA approved? No. Ipamorelin is not FDA approved as a drug for any indication, and it has never been approved by any regulatory authority worldwide. It was investigated — most notably for postoperative ileus, trial NCT00672074 — but that program ended after Phase 2 [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-drug-substances list, following the nominator's withdrawal in September 2024, and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and it is prohibited in sport at all times under the WADA list (category S2), detectable in urine by accredited laboratories. --- A vetted, combination-stacks-first reading of the ipamorelin record — the selective GH pulse and the CJC-1295 pairing examined in measured detail, ipamorelin's own studies kept distinct from its chemical relatives, and the popular protocols held to the trial that was never run on them; no clinic behind the name, no seller endorsed, and nothing here dosed, prescribed, or sold.